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Abstract 
Proliferation of pancreatic acinar cells is a critical process in the pathophysiology of pan-
creatic diseases, as limited or defective proliferation is associated with organ dysfunction 
and patient morbidity. In this context, elucidating the signalling pathways that trigger and 
sustain acinar proliferation is pivotal to develop therapeutic interventions promoting the 
regenerative process of the organ.  
In this study we used genetic and pharmacological approaches to manipulate both local 
and systemic levels of thyroid hormones to elucidate their role in acinar proliferation 
following cerulein-mediated acute pancreatitis in mice. In addition, molecular 
mechanisms mediating the effects of thyroid hormones were identified by genetic and 
pharmacological inactivation of selected signalling pathways. 
In this study we demonstrated that levels of the thyroid hormone 3,3’,5-triodo-L-thyronine 
(T3) transiently increased in the pancreas during acute pancreatitis. Moreover, by using 
genetic and pharmacological approaches to manipulate both local and systemic levels of 
thyroid hormones, we showed that T3 was required to promote proliferation of pancreatic 
acinar cells, without affecting the extent of tissue damage or inflammatory infiltration. 
Finally, upon genetic and pharmacological inactivation of selected signalling pathways, 
we demonstrated that T3 exerted its mitogenic effect on acinar cells via a tightly controlled 
action on different molecular effectors, including histone deacetylase, AKT, and TGFβ 
signaling. 
In conclusion, our data suggest that local availability of T3 in the pancreas is required to 
promote acinar cell proliferation and provide the rationale to exploit thyroid hormone 
signaling to enhance pancreatic regeneration. 
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Introduction  
Acute pancreatitis, a debilitating inflammatory disease of the pancreas, is a major cause 
of gastrointestinal hospital admission [1]. Pancreatic injury leads to dysfunctional pro-
cesses and, in severe circumstances, necrosis of exocrine pancreatic tissue, resulting in 
high morbidity and mortality. In this context, enhancing regeneration of the exocrine pan-
creas is a key therapeutic target to restore the activity of the organ and limit the patholog-
ical implications associated with impaired pancreatic function.  
We aimed to identify molecular factors that act as mitogens for pancreatic acinar cells 
and thus have the potential to be exploited therapeutically to promote pancreatic regen-
eration. Fully differentiated pancreatic acinar cells are able to transiently de-differentiate 
to a progenitor-like state and re-enter the cell cycle program in response to pancreatitis 
[2]. However, this proliferative ability, reported in human and animal models, is often lim-
ited, thus hampering the extent of pancreatic regeneration. In recent years multiple sig-
naling pathways and transcription factors have been described to be activated during 
acinar cell proliferation following pancreatitis (reviewed in [3]). Importantly, molecular fac-
tors involved in the process of regeneration in the adult pancreas are also implicated in 
the embryonic development of the organ. However, our knowledge regarding molecules 
that specifically trigger or sustain proliferation of acinar cells is still limited. In this study, 
we investigated whether a proliferative stimulus for acinar cells is provided by a local 
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increase of thyroid hormone levels in the pancreas upon induction of pancreatitis. The 
hypothesis of local hyperthyroidism to support pancreatic regeneration was built on inde-
pendent lines of evidence. Firstly, consistent with the fact that a developmental program 
is re-activated during pancreatic regeneration, thyroid hormones play a functional role in 
the development of pancreatic cells during organogenesis, demonstrated in both amphib-
ian and mammalian pancreas (reviewed in [4]). Secondly, adult acinar cells harbor the 
molecular machinery to respond to thyroid hormones and start proliferating when 3,3’,5-
triiodo-L-thyronine (T3), the biologically active thyroid hormone that binds to thyroid hor-
mone receptors [5], is administered exogenously [6, 7]. Finally, thyroid hormones act as 
mitogens during regeneration of adult liver [8], an organ that shares the same embryo-
logical lineage with the pancreas.  
To test our hypothesis that thyroid hormones are endogenous mitogens for pancreatic 
acinar cells during pancreatitis, we utilized genetic and pharmacological approaches to 
alter their local and systemic levels, and assessed acinar proliferation following cerulein-
induced pancreatitis, the most widespread experimental method to induce the disease in 
rodents [3]. 
 
Materials and methods 
Detailed materials and methods are described in Supplementary Information. 
Animal experiments 
All animal experiments were conducted in accordance with Swiss federal animal regula-
tions and approved by the cantonal veterinary office of Zurich. All studies involving ani-
mals are reported in accordance with the ARRIVE guidelines for reporting experiments 
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involving animals. Pancreatitis was induced with 50 µg/kg cerulein injections in adult male 
C57BL/6 mice, mice with inducible ablation of Deiodinase 3 in acinar cells (ELACre-
ERT2/D3flox/flox, D3KO) and mice with conditional ablation of TGFβ receptor II (TGF-RII KO) 
in the pancreas [9]. The CRE-negative littermates were used as controls.  
Hyperthyroidism and hypothyroidism were induced by administration of 400 µg/kg T3 and 
0.1% methimazole, respectively [10]. MS-275 and MK2206 were used to inhibit Class I 
histone deacetylase and AKT. 
Immunohistochemistry 
Histological analyses were performed on paraffin-embedded pancreas, as previously 
described [11]. 
Protein analyses 
Protein expression in tissue was quantified by western blotting using pancreas 
homogenates in RIPA buffer.  HDAC activity in pancreas was measured by ELISA assay. 
Enzyme activity in blood was quantified using clinical chemistry procedures. 
Transcript analyses  
Gene expression was quantified by qRT-PCR using Taqman probes (Applied 
Biosystems, Foster City, CA). Transcript levels were normalized using 18S RNA as a 
reference and expressed as 2-ΔΔCt relative to the value of control animals. 
Statistics  
Groups of five animals were tested for each experimental group. The data are expressed 
as means ± SEM. The statistical significance of differences in the means of experimental 
groups was determined using an unpaired, two-tailed Student's t test or one-way analysis 
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of variance followed by Dunnett post-test (GraphPad Prism 7; GraphPad Software, Inc.) 
and a probability value <0.05 was considered statistically significant. 
 
Results  
Local hyperthyroidism is induced in the pancreas during acute pancreatitis 
To test whether thyroid hormones act as mitogens during pancreatic regeneration upon 
inflammatory injury, we first investigated whether T3 levels increased in the pancreas 
following induction of acute pancreatitis with serial injections of cerulein. Cerulein 
administration (scheme depicted in Fig.1A) results in a time-dependent increase in acinar 
cell proliferation, as quantified by the levels of acinar cells positive for the general 
proliferation marker Ki67 (Fig.1B, S1A). Interestingly, we observed a transient surge of 
free T3 (F-T3) levels, the biologically active form of the hormone (reviewed in [5]), in the 
pancreas (Fig.1C), which preceded the peak of acinar cell proliferation. Conversely, 
levels of thyroid hormones F-T4 and F-T3 transiently decreased in blood (Fig.1D). 
Increased F-T3 levels in pancreatic tissue may derive from increased uptake from the 
circulation of either T3 and/or of T4, with  subsequent conversion into T3 by the action of 
deiodinases (DIO) enzymes, which regulate the intracellular hormone concentration in a 
time- and tissue-specific fashion, independently on the levels present in blood [5]. We 
detected an early up-regulation of Dio2, the enzyme responsible for local T4 to T3 
conversion in target cells [12], in the pancreas in response to induction of pancreatitis 
(Fig.1E). Importantly, Dio3, the expression of which increases upon hyperthyroid status 
[13-15], was also up-regulated in the pancreas. Dio3 increase is not only an indicator of 
local hyperthyroidism in the pancreas, but it likely limits the hormone increase, as it is the 
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major inactivating enzyme terminating the action of both T4 and T3 hormones [16].  
Finally, Dio1 expression was transiently down-regulated. The mechanisms of this down-
regulation are not completely elucidated, however it is possible that inflammatory 
cytokines released during pancreatitis contribute to reduce Dio1 expression, as previously 
reported in hepatocytes [17]. 
Dio2 and Dio3 up-regulation was also detected in pancreatic acinar cells isolated after 24 
h of cerulein treatment (Fig.1F), suggesting that acinar cells are able to regulate the 
intracellular concentration of thyroid hormones. Analyses of Dio expression in multiple 
organs revealed that gene regulation was either detected exclusively (Dio1, Dio2) or 
showing the highest regulation (Dio3) in the injured pancreas (Fig.1G).  
Collectively, these data support the hypothesis that increased levels of F-T3 and 
consequent local hyperthyroidism are specifically and transiently induced in the organ in 
response to acute pancreatitis.  
Genetic ablation of DIO3 in acinar cells increases acinar proliferation during acute 
pancreatitis  
To test whether the transient hyperthyroidism observed promotes acinar proliferation, we 
increased the levels of thyroid hormones in acinar cells by conditionally knocking out Dio3 
using a tamoxifen-inducible approach (scheme depicted in Fig.2A).  In the absence of 
pancreatitis, Dio3 conditional KO (D3KO) mice presented a normal phenotype 
indistinguishable from control mice. This was evident by normal pancreatic histology 
(Fig.2B), lack of acinar damage (Fig.S1A), and absence of inflammation (Fig.2C). 
Similarly, no differences in basal levels of acinar cell proliferation were observed between 
transgenic and control mice (Fig.2D), even one month after tamoxifen treatment 
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(Fig.S1B), suggesting that ablation of Dio3 does not compromise pancreatic homeostasis 
in untreated mice. Similarly, levels of pancreatic and circulating thyroid hormones were 
not altered in D3KO mice in untreated conditions (Fig.2E). However, upon induction of 
acute pancreatitis (treatment scheme depicted in Fig.2F), proliferation of acinar cells was 
higher in D3KO animals, as determined by the number of Ki67 positive cells (Fig. 2G) 
and cyclin expression in the pancreas (Fig.2H). Consistent with Dio3 ablation, D3KO 
animals showed increased levels of F-T3 in the pancreas (Fig.2I). The limited extent of 
T3 increase is likely the result of the relatively low recombination efficiency reported for 
this line [18, 19]. Increased acinar proliferation was not a consequence of increased 
pancreatic injury upon induction of pancreatitis, as blood levels of amylase and lipase, 
the most reliable indicators of acinar cell damage, were comparable in control and D3KO 
mice (Fig.2J). Similarly, increased proliferation was not driven by increased recruitment 
of PU.1-positive inflammatory cells, as their number was comparable in the two strains 
(Fig.2K). Finally, increased acinar proliferation was not accompanied by changes in the 
levels of acinar-to-ductal metaplasia (ADM) (Fig.2L), a transient de-differentiation of 
acinar cells observed in the tissue during pancreatic regeneration. Collectively, these data 
indicate that ablation of Dio3 in acinar cells is sufficient to increase pancreatic levels of F-
T3 and to enhance acinar proliferation upon induction of acute pancreatitis.  
   
Systemic alterations of thyroid hormone levels modulate acinar cell proliferation 
during acute pancreatitis 
After showing that local hyperthyroidism supports acinar proliferation, we then 
investigated whether systemic alteration of thyroid hormone levels affect the extent of 
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acinar proliferation during the disease. Systemic hyperthyroidism was induced by daily 
administration of T3 starting after the first set of cerulein injections, while systemic 
hypothyroidism was induced by administration of NaClO4 and methimazole (MMI) for 28 
days (regimen scheme depicted in Fig.3A). Analysis of thyroid hormone levels in serum 
confirmed the efficacy of the treatments as T3 administration increased F-T3 levels and 
decreased F-T4, as a consequence of negative feedback loop, while MMI administration 
decreased the levels of both hormones (Fig.3B).  
T3 treatment significantly increased proliferation of acinar cells (Fig.3C, S2A), and cyclin 
expression in the pancreas (Fig.3D). Conversely, MMI administration decreased both 
acinar proliferation and cyclin expression (Fig.3C, D). In addition, thyroid hormone 
alterations did not affect the average size of acinar cells (Fig. S2B), suggesting that this 
parameter is not correlated with the level of cell proliferation. 
Administration of T3 to hypothyroid mice rescued the defective acinar proliferation 
(Fig.3E), further demonstrating that increased levels of this hormone are sufficient to 
boost acinar cell proliferation. 
The observed changes in acinar proliferation were not a consequence of changes in initial 
damage of acinar cells or infiltration of inflammatory cells, as shown by comparable levels 
of serum amylase and lipase (Fig.3F). Levels of lactate dehydrogenase (LDH), an 
additional marker of tissue damage, were also comparable 8 hours after induction of 
pancreatitis (Fig. S3). Furthermore, differences in acinar replication were not correlated 
to differences in infiltration of PU.1-positive inflammatory cells (Fig.3G), acinar apoptosis 
(Fig.S4A) or DNA damage (Fig.S4B). Collectively, these data suggest that altering the 
systemic levels of thyroid hormones does not modify pancreatic sensitivity to cerulein 
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administration and recruitment of inflammatory cells. In addition, changes in acinar 
proliferation induced by systemic variation of thyroid hormone levels are independent 
from the levels of acinar cell injury and inflammatory cell infiltration. 
Finally, to demonstrate that T3 sustains acinar cell proliferation independently from T4, 
we administered Iopanoic acid (IOP), a specific deiodinase inhibitor that blocks T4 to T3 
conversion [20], in combination with cerulein (Fig.3H). Analysis of thyroid hormone levels 
confirmed that IOP administration decreased blood levels of F-T3, whereas F-T4 amount 
was unchanged (Fig.3I). Similar to what we observed in hypothyroid mice, IOP-treated 
animals showed a significant decrease in the number of proliferating acinar cells (Fig.3J). 
Overall, these data demonstrate the existence of a positive correlation between thyroid 
hormone levels, in particular T3 availability, and proliferation of acinar cells in response 
to acute pancreatitis.  
Acinar proliferation induced by T3 administration is promoted by HDAC activity 
and AKT signaling  
Next, we investigated the molecular mechanisms underlying the mitogenic action of T3 in 
pancreatic acinar cells. To focus exclusively on T3 action without the confounding aspect 
of pancreatic inflammation, we supplemented T3 in vivo in the absence of cerulein-
induced pancreatitis (scheme depicted in Fig.4A). Analysis of acinar cells positive for 
proliferation markers Ki67 and pH3 (Fig.4B) and pancreatic expression of early and late 
cyclins (Fig.S5A) showed that T3 exerted a profound mitogenic effect on acinar cells 96 
hours after the beginning of the treatment, as previously described [6]. Moreover, T3-
mediated induction of acinar proliferation was dose-dependent (Fig.4C) and it did not 
elicit inflammatory cell infiltration (Fig.4D) or morphological alteration of pancreatic tissue 
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(Fig.S5B), which further support our observation that T3 does not influence pancreatic 
inflammation during the development of pancreatitis. As previously reported, systemic 
administration of T3 results in proliferation of different cell types, including cardiomyocytes 
[21-23] (Fig.S6A). However, T3 did not stimulate the replication of pancreatic islet cells 
in our experimental conditions (Fig. S6B). 
T3 regulates multiple pathways within the cells by genomic and non-genomic actions [24]. 
Here we tested whether T3 activates signaling pathways that are known to support acinar 
proliferation during pancreatitis. We first assessed whether T3 administration triggered 
the upregulation of histone deacetylases (HDAC), a class of epigenetic modifiers 
activated during pancreatitis and promoting proliferation of acinar cells [25, 26]. T3 
treatment was sufficient to increase both the expression of different HDAC isoforms 
(Fig.4E) and total HDAC activity in the pancreas (Fig.4F). In vivo treatment with the 
specific class I HDAC inhibitor MS-275 (treatment scheme depicted in Fig.S7A) 
effectively reduced HDAC activation (Fig.S7B) and reduced acinar cell proliferation 
(Fig.4G), suggesting that increased HDAC activity is required for the mitogenic effect 
mediated by T3. At the molecular level, inhibition of acinar cell proliferation was 
accompanied by reduced cyclin B expression (Fig.S7C) and increased expression of cell 
cycle inhibitors, including p15 (Cdkn2b), p16 (Cdkn2a), and p18 (Cdkn2c) (Fig.S7D). 
We then investigated whether T3 administration promoted the activation of 
phosphatidylinositol 3-kinase (PI3K)/AKT signaling. The AKT pathway is important for 
pancreatic proliferation, as reduction of this signaling suppresses acinar cell division [27] 
and its constitutive activation in adult acinar cells leads to excessive proliferation and 
malignant transformation [28]. T3 supplementation significantly increased pancreatic 
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gene expression of Akt1 and Akt2 isoforms (Fig.4H), AKT protein levels and AKT 
activation via phosphorylation (Fig.4I). To test the functional relevance of AKT signaling, 
we administered the potent pan-AKT inhibitor MK-2206, effective in vivo [29]. MK-2206-
treated mice (treatment scheme depicted in Fig.S8A) showed reduced AKT activation 
(Fig.4J), confirming the efficacy of the compound. Importantly, MK-2206 treatment 
strongly reduced acinar cell proliferation (Fig.4K) and cyclin expression (Fig.S8B) while 
increasing the expression of the cell cycle inhibitors p15 (Cdkn2b),  and p16 (Cdkn2a), 
(Fig.S8C), which could likely contribute to the observed inhibition of proliferation.  
Collectively, these data demonstrate that T3 promotes the proliferation of healthy acinar 
cells by activating signaling pathways known to support acinar proliferation during 
pancreatitis. 
 
Acinar proliferation induced by T3 administration is restrained by TGFβ signaling.  
We then investigated whether pathways inhibiting cell proliferation are also engaged upon 
T3 administration. This is an important component in organ regeneration as activation of 
pro- and anti-mitogenic signaling is also observed during pancreatitis, thus resulting in a     
tightly controlled acinar cell proliferation.  Transforming Growth Factor beta (TGFβ) 
signaling via TGFβ receptor II is activated in pancreatic cells during cerulein-induced 
pancreatitis and it reduces acinar cell proliferation [9]. Expression levels of TGFβ1–3 
isoforms increased in the pancreas at 96 hours following T3 supplementation (Fig.5A). 
However, increased expression of TGFβ isoforms was not accompanied by a robust 
increase in phosphorylation of SMAD effector proteins at this time point (Fig.5B), 
suggesting that activation of TGFβ signaling is blunted in the presence of T3. 
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To investigate whether the observed upregulation of TGFβ exerts an anti-mitogenic 
action, we assessed the levels of T3-induced acinar cell proliferation in mice lacking TGFβ 
signaling following ablation of TGFβ receptor II in the pancreas, which we characterized 
previously in the context of pancreatitis [9] (scheme depicted in Fig.5C). Similar to what 
we observed upon cerulein administration and inflammatory injury, acinar proliferation 
induced by T3 treatment increased in the absence of TGFβ receptor II, as quantified by 
the levels of proliferation markers (Fig.5D) and cyclin expression (Fig.S9A). T3 treatment 
did not change robustly the expression of cell cycle inhibitors (Fig.S9B). Overall, our data 
suggest that acinar cell proliferation induced upon T3 administration is restrained by 
TGFβ signaling.  
 
Discussion 
Thyroid hormones play essential roles in the embryonic and adult homeostasis across 
species, by regulating the development of several organs, growth and metabolic pro-
cesses [12]. 
Here we showed that thyroid hormone signaling is activated during the pathological set-
ting of pancreatitis where it promotes pancreatic acinar cell proliferation.  
These findings have important implications for translational application in a therapeutic 
setting, as defective or limited acinar proliferation is at the core of morbidity associated 
not only with acute pancreatitis but also with acinar atrophy and exocrine pancreatic in-
sufficiency found in a broader range of pancreatic diseases, including chronic pancreati-
tis, diabetes and cystic fibrosis. 
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Our results highlight three major concepts that demonstrate the profound effect exerted 
by thyroid hormones in the pathophysiology of pancreatitis. Firstly, we showed that levels 
of F-T3, the biologically active form of thyroid hormones, transiently increased in the pan-
creas following inflammatory injury. This local hyperthyroidism was determined by direct 
quantification of the hormone in the tissue, by organ-specific up-regulation of enzymes 
responsible for thyroid hormone synthesis (reported also in a recently transcriptome-
based study [30]) and by up-regulation of thyroid hormone inactivating enzyme de-
iodinase 3, an accurate functional marker of thyroid hormone status [31, 32]. 
The increase of F-T3 levels in the injured pancreas was independent from circulating 
levels of thyroid hormones, which decreased in the initial stages of the disease. This sug-
gests that serum hormone levels are not a direct measure of the intracellular T3 availa-
bility in the organ. In addition, the transient nature of T3 increase in the organ implies that 
the concentration and consequent signaling of the hormone is controlled by the activity of 
both activating and inactivating deiodinases engaged in a time-dependent manner in the 
tissue, as further supported by our deiodinases expression data.  
Secondly, we revealed that selectively increasing F-T3 levels in the pancreas, by reducing 
deiodinase 3-dependent T3 inactivation, boosted acinar proliferation in the context of pan-
creatic injury. This mitogenic effect was exquisitely acinar-specific, as it did not affect 
replication of non-acinar cells and was not accompanied by changes in tissue damage, 
infiltration of inflammatory cells, or trans-differentiation of acinar cells into ADM. In addi-
tion, we showed that deiodinase 3 ablation in untreated conditions did not increase T3 
levels in the pancreas nor induced proliferation of acinar cells, suggesting that an initial 
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pancreatic damage is necessary to trigger local hyperthyroidism and its consequent mi-
togenic effects. 
Thirdly, we demonstrated that manipulating the circulating levels of thyroid hormones had 
a direct impact on acinar cell proliferation.  This raises the important clinical implication 
that hypothyroid patients may suffer from impaired acinar proliferation in the context of 
pancreatitis. This potential concern complements previous reports showing that low thy-
roid hormone levels in acute pancreatitis patients are a marker for increased severity of 
the disease [33, 34]. 
Collectively, our data showing enhanced acinar proliferation induced by both tissue spe-
cific and systemic elevation of thyroid hormones provide a proof of concept for a potential 
therapeutic target to improve organ regeneration. While systemic T3 administration did 
not provoke adverse outcomes of tissue damage or inflammation (our study and [6, 7]), 
T3 exerts mitogenic effects in different organs. Thus, future research should focus on the 
development of therapeutic interventions promoting proliferation of acinar cells in a se-
lective manner during the regenerative phase of the organ. In this context, our data sug-
gest that inhibition of deiodinase 3 activity is an appealing target to increase T3 levels 
locally in the pancreas, as its expression was greatly up-regulated in the injured organ 
and its ablation was sufficient to increase acinar proliferation. 
An additional focus of our study was to identify molecular pathways activated during T3-
induced acinar proliferation. By using the controlled setting of T3 administration in the 
absence of pancreatitis, we demonstrated that T3 triggers the production of several 
signaling molecules, the activity of which either promotes or reduces acinar proliferation. 
This array of regulatory mechanisms provides the underlining explanation for the fact that 
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T3-induced acinar proliferation is a temporally controlled process. Importantly, they 
revealed that the signaling pathways activated by T3 are also crucial in regulating acinar 
proliferation in the context of pancreatitis [9, 26, 27], further supporting the concept that 
T3 is a major factor in driving acinar cell division upon inflammatory insult. 
Amongst the pathways identified, we discovered that T3-induced acinar proliferation is 
promoted by the activity of the epigenetic modifier class I HDACs and by AKT signaling. 
HDACs are known members of the thyroid receptor co-repressor complex regulating the 
genomic effects of T3-induced transcription [35], while AKT signaling is considered an 
example of non-genomic actions of thyroid hormones, which are rapid in their onset and 
independent from nuclear uptake of T3 (reviewed in [24, 36]). Thus, the dual activation of 
genomic and non-genomic pathways suggests that both modality of T3 signaling are 
engaged in the pancreas to drive acinar proliferation. This is consistent with AKT 
contributing to mediate the effects of T3 administration reported in other tissues and cells, 
including skeletal muscle [37], heart [38] and fibroblasts [39], suggesting that activation 
of non-genomic actions is a common pathway in T3-mediated signaling. 
The third signaling pathways we identified in the pancreas in response to T3 
administration is TGFβ. Interestingly, while TGFβ isoforms were upregulated during T3 
treatment, activation of TGFβ signaling was blunted. This in agreement with a previous 
report showing that T3 antagonizes TGFβ signaling by reducing SMAD phosphorylation 
[40]. The functional relevance of this signaling inhibition is likely to promote acinar 
proliferation, as defective TGFβ receptor potentiated the mitogenic effect of T3 in acinar 
cells. In this context, it is tempting to speculate the existence of a negative feedback loop 
where TGFβ is upregulated as a consequence of T3-driven proliferation and it acts as a 
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repressor of cell division. Interestingly, the cross-talk between T3 and TGFβ is not always 
of antagonistic nature. As an example, T3 administration activates TGFβ signaling in 
hepatocellular carcinoma and results in reduced cell proliferation [41].  
Conclusions 
Based on our collective results, we propose that establishment of a time-dependent and 
tightly controlled local hyperthyroidism in the pancreas supports acinar proliferation fol-
lowing injury. This discovery harbors therapeutic implications and highlights the potential 
of interventional strategies based on the modulation of thyroid hormonal signal to promote 
pancreatic regeneration. 
The mitogenic effect exerted by T3 in adult pancreatic acinar cells is shared by several 
tissues and cell types, including renal proximal tubular epithelial cells [7], heart cells [42], 
liver cells [43-45]. However, a different situation is observed during muscle regeneration, 
where T3 is required to differentiate the local population of satellite stem cells into mature 
muscle cells [46]. Similarly, low levels of thyroid hormones maintain the renewal capacity 
of oligodendrocyte progenitor cells, while their elevation promotes the switch from stem 
cell proliferation to cell differentiation [47]. Intriguingly, but not entirely surprising given the 
pivotal role of cancer stem cells to self-renew and drive tumorigenesis [48], low levels of 
thyroid hormones are required to support the development of different malignancies (re-
viewed in [49]).  
Thus, our results contribute to expand the concept that thyroid hormones induce different 
outcomes in different replicative contexts where they control the balance between 
proliferation and differentiation. While this study provides the first insight into endocrine 
regulation of acinar proliferation, further studies are required to elucidate fully the details 
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of thyroid hormone actions in the pancreas. An open question not addressed in our study 
is the identification of the thyroid hormone receptors involved in the observed phenotype 
and the characterization of their cistromes in vivo. This is of special interest as the 
receptor isoforms have different repertoires of target genes [50], the expression of which 
can be affected by  thyroid hormone binding in either a positive or negative manner [51]. 
Another open question concerns the role of transmembrane transporters for thyroid hor-
mones [52, 53] in regulating hormone availability in the pancreas. While a thorough char-
acterization of transporter families has not been performed in acinar cells, it is worth 
mentioning that amongst the L-type amino acid transporters involved in thyroid hormone 
uptake, Lat1 and Lat2 are expressed on the basolateral membrane of adult acinar cells 
[54]. 
Finally, the investigation of the upstream signals that regulate expression of deiodinases 
in the injured pancreas is of major interest. Their identification is crucial not only to under-
stand how the onset of local hyperthyroidism takes place, but also to identify possible 
targets to exploit as therapeutic intervention. 
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Figure legends 
Figure 1. Pancreatic levels of F-T3 increase following cerulein-induced pancreatitis. 
(A) Schematic representation of cerulein (Cer) administration. Mice received six injections 
daily over two consecutive days. Harvest time is indicated as hours after the first cerulein 
injection. (B) Quantification of acinar cells positive for the replication marker Ki67 at the 
indicated time after cerulein administration. Right panels, representative microphotograph 
of stained cells (partial field of view). A complete field of view of a microphotograph used 
for cell counting is shown in Fig. S1A. (C) Quantification of free T3 (F-T3) in the pancreas 
at the indicated time after cerulein administration. (D) Quantification of free T4 and free 
T3 in the mice sera at the indicated time after cerulein administration. (E) qPCR of 
deiodinase (DIO) 1-3 in the pancreas at the indicated time after cerulein administration. 
(F) qPCR of deiodinase (DIO) 1-3 in pancreatic acini isolated 24 hours after cerulein 
administration. Right panel, representative microphotographs of isolated acini. (G) qPCR 
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of deiodinase (DIO) 1-3 in different organs at the indicated time after cerulein 
administration. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 µm. 
Figure 2. Ablation of deiodinase 3 in acinar cells increases acinar proliferation 
following induction of pancreatitis. (A) Schematic representation of conditional 
deiodinase 3 knocked out breeding. (B) Hematoxylin and Eosin (H&E) staining of 
pancreata in wild type (WT) and deiodinase 3 knocked out (D3KO) mice in untreated 
conditions (partial field of view). (C) Quantification of PU.1-positive inflammatory cells in 
untreated WT and D3KO mice. Right panels, representative microphotographs of stained 
cells (arrows) (partial field of view). (D) Quantification of Ki67-positive acinar and 
interstitial cells in untreated mice. Right panels, representative microphotographs of 
stained acinar (arrows) and interstitial (arrowheads) cells (partial field of view).  (E) 
Quantification of pancreatic and serum levels of free T3 (F-T3) and free T4 (F-T4) in 
untreated mice. (F) Schematic representation of induction of pancreatitis with cerulein 
injections in WT and D3KO mice. (G) Quantification of Ki67-positive acinar cells at the 
indicated time following induction of pancreatitis. Right panels, representative 
microphotographs of stained cells 96h after pancreatitis induction (partial field of view).  
(H) qPCR of cyclin expression in the pancreas at the indicated time following induction of 
pancreatitis. Cyclin A (Ccna1), cyclin B (Ccnb1), cyclin D (Ccnd1), cyclin E (Ccne1). (I) 
Quantification of free T3 in the pancreas at the indicated time following induction of 
pancreatitis. (J) Quantification of amylase and lipase activity in serum at the indicated 
time following induction of pancreatitis. (K) Quantification of PU.1-positive inflammatory 
cells at the indicated time after induction of pancreatitis. Right panels, representative 
microphotographs of stained cells (arrows) (partial field of view). (L) Quantification of 
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ADM 96 hours after induction of pancreatitis. Right panel, representative 
microphotograph of ADM area (asterisk) (partial field of view). Results are average ± SEM 
(n=5), *P < 0.05. Scale bars: 50 µm. 
Figure 3. Systemic alteration of thyroid hormone levels affects acinar proliferation 
following induction of pancreatitis. (A) Schematic representation of pancreatitis 
induction upon hyperthyroidism (i) and hypothyroidism (II) with T3 and MMI 
administration, respectively. (B) Quantification of serum levels of free T4 (F-T4) and free 
T3 (F-T3) 96 hours after induction of pancreatitis. (C) Quantification of Ki67 and pH3-
positive acinar cells 72 and 96 hours after induction of pancreatitis. Left panels, 
representative microphotographs of stained cells 96 hours after pancreatitis induction 
(partial field of view).  (D) qPCR of cyclin expression in the pancreas at the indicated time 
following induction of pancreatitis. Cyclin A (Ccna1), cyclin B (Ccnb1), cyclin D (Ccnd1), 
cyclin E (Ccne1). (E) Quantification of Ki67-positive acinar cells 96 hours after induction 
of pancreatitis. (F) Quantification of amylase and lipase activity in serum at the indicated 
time following induction of pancreatitis. (G) Quantification of PU.1-positive inflammatory 
cells at the indicated time after induction of pancreatitis. (H) Schematic representation of 
pancreatitis induction upon IOP treatment. (I) Quantification of serum levels of free T4 (F-
T4) and free T3 (F-T3) at the indicated time after induction of pancreatitis. (J) 
Quantification of Ki67 and pH3-positive acinar cells at the indicated time after induction 
of pancreatitis. Right panels, representative microphotographs of stained cells 96 hours 
after induction of pancreatitis (partial field of view).  Results are average ± SEM (n=5), *P 
< 0.05. Scale bars: 50 µm. 
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Figure 4. T3-induced acinar proliferation is supported by HDAC activity and AKT 
signaling. (A) Schematic representation of T3 treatment. (B) Quantification of Ki67 and 
pH3-positive acinar cells 96 hours after 400 µg/kg T3 treatment. (C) Quantification of 
Ki67-positive acinar cells 96 hours after T3 treatment at the indicated concentrations. (D) 
Quantification of PU.1-positive inflammatory infiltrating the pancreas 96 hours after T3 
treatment. (E) qPCR of class I and class II HDAC expression in the pancreas 96 hours 
after T3 treatment. (F) Quantification of HDAC activity in the pancreas 96 hours after T3 
treatment. (G) Quantification of Ki67 and pH3-positive acinar cells 96 hours after T3 
treatment in the presence of the selective class I HDAC inhibitor MS-275 (MS). Right 
panels, representative microphotographs of stained cells (partial field of view).  (H) qPCR 
of AKT isoform expression in the pancreas 96 hours after T3 treatment. (I) Western blot 
analyses of AKT expression and activation in the pancreas 96 hours after T3 treatment. 
(J) Western blot analyses of AKT activation in the pancreas 96 hours after T3 treatment 
in the presence of the selective AKT inhibitor MK-2206 (MK). (K) Quantification of Ki67 
and pH3-positive acinar cells 96 hours after T3 treatment in the presence of the selective 
AKT inhibitor MK-2206 (MK). Right panels, representative microphotographs of stained 
cells (partial field of view).  Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 
µm. 
Figure 5. T3-induced acinar proliferation is restrained by TGFβ signaling. (A) qPCR 
of TGFβ isoform expression in the pancreas 96 hours after T3 treatment. (B) Western 
blot analyses of SMAD expression and activation in the pancreas 96 hours after T3 
treatment. (C) Schematic representation of T3 treatment in wild type (WT) and TGFβ 
receptor II knocked out mice (KO). (D) Quantification of Ki67 and pH3-positive acinar cells 
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96 hours after T3 treatment in WT and KO mice. Right panels, representative 
microphotographs of stained cells (partial field of view). Results are average ± SEM (n=5), 
*P < 0.05. Scale bars: 50 µm. 
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Figure 5 
SUPPLEMENTARY INFORMATION 
MATERIALS AND METHODS 
Animal experiments 
Mice used in this study were C57BL/6 mice (Envigo, Itingen, Switzerland), TGF-RII 
KO mice bred in our facility by crossing mice expressing TGFβ receptor IIflox/flox with 
mice harbouring pancreas transcription factor 1a (PTF1a) promoter Cre transgene 
(PTF1acre; MMRRC, USA), and D3KO mice bred in our facility. D3KO animals were 
generated by crossing mice harboring elastase (ELA) promoter driven Cre transgene 
ELACreERT2Tg/+ [19] with  transgenic mice expressing Deiodinase 3 flox/flox  [45]. 
Tamoxifen (Sigma-Aldrich, Buchs, Switzerland)-driven recombination was induced 
with 100 µL injection of 20 mg/mL tamoxifen daily for five consecutive days as 
described [55]. 
Acute pancreatitis was induced via six intraperitoneal (i.p.) injections of 50 µg/kg 
cerulein (Sigma-Aldrich, Buchs, Switzerland), administered hourly on two consecutive 
days. Control animals received 0.9% NaCl injections. Hyperthyroidism was induced 
with daily injections of 400 µg/kg T3 (Sigma-Aldrich, Buchs, Switzerland). Control 
animals received vehicle 0.1 M NaOH, pH 7.4 with 0.5% BSA injections. 
Hypothyroidism was induced by administration of 1% NaClO4 and 0.1% methimazole 
(MMI, Sigma-Aldrich, Buchs, Switzerland) in drinking water for 28 days [10]. 
Class I histone deacetylase (HDAC) inhibitor MS-275 (Selleckchem, Houston, USA) 
was injected daily i.p. at 20 mg/kg, starting one day before the first T3 injection (See 
scheme Fig.S4). 
Akt inhibitor MK-2206 (A3010, APExBIO, Houston, USA) was injected four times daily 
i.p. at 8 mg/kg, starting before the first T3 injection (see scheme Fig.S5). 
 
Immunohistochemistry 
Primary antibodies used in this study were: rabbit anti-Ki67 (#ab16667, Abcam, 
Cambridge, UK, 1:200); rabbit anti-phospho-H3(06-570, Millipore); rabbit anti-amylase 
(#A8273-1VL, Sigma-Aldrich, Buchs, Switzerland, 1:1000); rabbit anti-PU.1 (#2266, 
Cell Signaling Technologies, Danvers, MA, 1:200); rabbit anti-phospho-histone H2A.X 
(Ser139) (#9718, Cell Signaling Technologies, Danvers, MA, 1:500); rabbit anti-
cleaved Caspase-3 (Asp175) (#9661, Cell Signaling Technologies, Danvers, MA, 
1:1500). Secondary antibodies used in this study were biotinylated goat anti-rabbit IgG 
(H + L), included in the Vectastain® ABC Kit (PK-4001, Vector Laboratories, 
Peterborough, UK). All staining, with the exception of amylase, was performed with a 
DAKO autostainer Link 48 (Glostrup, Denmark). 
Microscopy analyses were performed on a wide-field Nikon Eclipse Ti (Amsterdam, 
The Netherlands). Quantification of labelled cells was performed in at least ten 
randomly selected high-power fields (×200) per slide using the NIS Elements BR 
Analysis (Nikon, Amsterdam, The Netherlands) and Cell^P (Olympus, Tokyo, Japan) 
analysis software. Number of positive cells was normalized based upon the area 
exclusively occupied by pancreatic acinar tissue present in each power field. Area 
occupied by pancreatic ducts, islets and vessels were excluded from the analysis. 
Quantitative analysis of acinar-to-ductal metaplasia (ADM) was performed as 
described in an earlier paper from our group [56]. Briefly, paraffin-embedded pancreas 
specimens were immunostained for amylase, slides were scanned with a NDP 
NanoZoomer Digital Pathology Slide Scanner (Hamamatsu, Solothurn, Switzerland) 
and analyzed for ADM lesions in a blinded fashion. ADM present in the entire pancreas 
slide of individual mice were quantified by manual counting. ADM were identified 
according to: i) loss of amylase content, ii) structural re-organization into tubular 
complexes, iii) stromal reaction characterized by presence of cell infiltrates. The area 
occupied by ADM was expressed as a percentage of total pancreatic area present in 
each slide. 
Western blotting 
Twenty mg of pancreatic tissue was homogenized in RIPA buffer containing a 
protease inhibitor cocktail (Roche Diagnostics, Rotkreuz, Switzerland). Protein 
concentrations were determined by a Bradford protein assay (BioRad, Hercules, CA). 
20 µg of proteins were resolved by SDS-PAGE electrophoresis and blotted onto 
nitrocellulose membranes using a V3 Western Workflow system (BioRAd, Hercules, 
CA) according to the manufacturer's protocols. Membranes were incubated with 
primary antibodies overnight at 4°C. Primary antibodies used in this study were: 
phospho-AKT (4051, Cell Signaling, Danvers, MA); AKT (9272, Cell Signaling, 
Danvers, MA); α-tubulin (2125, Cell Signaling, Danvers, MA); phospho-SMAD2/3 
(Ser423/425) (8828, Cell Signaling, Danvers, MA); SMAD2/3 (8685, Cell Signaling, 
Danvers, MA). 
Transcript analyses  
Total RNA was extracted from pancreatic tissue, as described previously [57], and 
RNA quality control was performed by RIN (RNA Integrity Number) measurement 
using a 2100 Bioanalyzer system (Agilent, Santa Clara, CA). RNA was reverse-
transcribed with qScript™ cDNA SuperMix (Quanta Biosciences, Beverly, MA). Gene 
expression was measured by real-time PCR on a 7500 Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA).  
Biochemical analyses 
Levels of enzymatic activity of amylase, lipase and LDH were measured in blood 
serum collected via heart puncture. Enzyme activities were measured using the Fuji 
Dri-Chem 4000i analyzer (FUJIFILM Corporation, Tokyo, Japan).  
Blood levels of F-T4 and F-T3 were quantified with Cobas 8000 Modular-System e602 
analyzer (Roche Diagnostics, Rotkreuz, Switzerland), according to the manufacturer’s 
instructions. 
Tissue levels of F-T3 were measured using an Elisa Kit (CUSABIO Technology LLC, 
Houston, TX) according to the manufacturer instruction. 
Nuclear protein extraction and HDAC activity 
Nuclear proteins were extracted from 20 mg of pancreatic tissue with the EpiQuik™ 
Nuclear Extraction Kit (Epigentek Group Inc., Mountain View, CA) and HDAC activity 
was measured in the nuclear extracts with the fluorimetric EpiQuik HDAC 
Activity/Inhibition Assay Kit (Epigentek Group Inc. Mountain View, CA), following the 
manufacturer's instructions.  
SUPPLEMENTARY FIGURE LEGENDS 
Figure S1. (A) Representative microphotographs of Ki67 stained cells (complete field 
of view). (B) Quantification of amylase and lipase activity in serum in untreated mice. 
(C) Quantification of Ki67 and pH3-positive acinar cells in untreated mice, one month 
after tamoxifen treatment. Right panels, representative microphotographs of stained 
cells.  Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 µm. 
Figure S2. (A) Quantification of Ki67-positive acinar cells, expressed as percentage 
of total acinar cell number, 96 hours after induction of pancreatitis upon 
hyperthyroidism and hypothyroidism with T3 and MMI administration, respectively. (B) 
Quantification of acinar cell size 96 hours after induction of pancreatitis. Results are 
average ± SEM (n=5), *P < 0.05. 
Figure S3. Quantification of lactate dehydrogenase (LDH) activity in serum 8 hours 
after induction of pancreatitis. Results are average ± SEM (n=5), *P < 0.05. 
Figure S4. (A) Quantification of acinar cells positive for the apoptotic marker cleaved 
caspase 3, 96 hours after induction of pancreatitis. Right panel, representative 
microphotographs of stained cell. (B) Quantification of acinar cells positive for the DNA 
damage marker pH2AX 96 hours after induction of pancreatitis. Right panels, 
representative microphotograph of stained cell.  Results are average ± SEM (n=5), *P 
< 0.05. Scale bars: 50 µm. 
Figure S5. (A) qPCR of cyclin expression in the pancreas 96 hours after T3 
administration. Cyclin A (Ccna1), cyclin B (Ccnb1), cyclin D (Ccnd1), cyclin E (Ccne1). 
(B) Hematoxylin and Eosin (H&E) staining of pancreata 96 hours after T3 
administration. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 µm. 
Figure S6. (A) Representative microphotograph of Ki67 stained cells in the heart 96 
hours after T3 administration. (B) Quantification of Ki67-positive islet cells at the 
indicated time of T3 administration. Right panel, representative microphotograph of 
Ki67 stained cells in the pancreas 96 hours after T3 administration.Arrow, islet of 
Langherans. Results are average ± SEM (n=5), *P < 0.05. Scale bars: 50 µm. 
Figure S7. (A) Schematic representation of T3 treatment in the presence of the 
selective class I inhibitor MS-275 (MS). (B) Quantification of HDAC activity in the 
pancreas 96 hours after T3 treatment in the presence of MS. (C) qPCR of cyclin 
expression in the pancreas 96 hours after T3 treatment in the presence of MS. Cyclin 
A (Ccna1), cyclin B (Ccnb1), cyclin D (Ccnd1), cyclin E (Ccne1). (D) qPCR of cell cycle 
inhibitor expression in the pancreas 96 hours after T3 treatment in the presence of 
MS. Results are average ± SEM (n=5), *P < 0.05. 
Figure S8. (A) Schematic representation of T3 treatment in the presence of the 
selective AKT inhibitor MK-2206 (MK). (B) qPCR of cyclin expression in the pancreas 
96 hours after T3 treatment in the presence of MK. Cyclin A (Ccna1), cyclin B (Ccnb1), 
cyclin D (Ccnd1), cyclin E (Ccne1). (C) qPCR of cell cycle inhibitor expression in the 
pancreas 96 hours after T3 treatment in the presence of MK. P15 (Cdkn2b), p16 
(Cdkn2a), p18 (Cdkn2c), p21 (Cdkn1a), p27 (Cdkn1b). Results are average ± SEM 
(n=5), *P < 0.05. 
Figure S9. (A) qPCR of cyclin expression in the pancreas 96 hours after T3 treatment 
in wild type (WT) and TGFβ receptor II deficient (KO) mice. (C) qPCR of cell cycle 
inhibitor expression in the pancreas 96 hours after T3 treatment. P15 (Cdkn2b), p16 
(Cdkn2a), p18 (Cdkn2c), p21 (Cdkn1a), p27 (Cdkn1b). Results are average ± SEM 
(n=5), *P < 0.05. 
 
 
 



 
